The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by hundreds or thousands ...
The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the ...
CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...
Agency commissioners voted unanimously on Tuesday to publish the report, which makes a similar attack on the drug middlemen ...
Newer entrants to the pharmacy benefit management market will continue to face stiff competition in 2025 as they seek more ...
CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal ...